Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT07300553 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT07300553
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Healthy volunteers may be considered if they:

  • Are aged 18 or older but under 50 years old
  • Have a body mass index (BMI) between 17 and 25 kg/m² (a measure of body weight relative to height)
  • Are a woman of childbearing age using an effective form of contraception (such as hormonal methods, an intrauterine device, a procedure to block the fallopian tubes, or complete abstinence from heterosexual intercourse) for at least the treatment period of the study
  • Have regular bowel movements — at least one stool every two days and no more than three stools per day
  • Have health insurance coverage (excluding AME)
  • Are willing and able to provide written informed consent

People with Inflammatory Bowel Disease (IBD) — a condition causing long-term inflammation in the digestive system — may be considered if they:

  • Are aged 18 or older but under 50 years old
  • Have a confirmed diagnosis of Crohn's disease (not limited only to the upper digestive tract) or ulcerative colitis (not limited only to the rectum) for at least 6 months, based on recognised medical criteria
  • Have been in remission (their condition has been stable and not actively flaring) for at least 6 months, without the use of steroid medications, and confirmed by specific disease activity scores (confirm with trial site)
  • Have a BMI between 17 and 25 kg/m²
  • Are a woman of childbearing age using a highly effective form of contraception, such as oral contraception, an intrauterine device, a hormonal device, sterilisation, or another method with a failure rate of less than 1%
  • Have regular bowel movements — at least one stool every two days and no more than three stools per day
  • Have health insurance coverage (excluding AME)
  • Are willing and able to provide written informed consent

Who may not be able to join:

Healthy volunteers may not be eligible if they:

  • Have a significant long-term illness, particularly a chronic digestive condition, type 1 or type 2 diabetes, or a kidney problem
  • Are currently taking any long-term treatment for a medical condition
  • Are pregnant or breastfeeding
  • Have donated blood in the three months before the study starts
  • Have taken antibiotic or antifungal medication by mouth in the three months before the first study visit
  • Have taken probiotic supplements in the month before the first study visit
  • Have followed a low-calorie diet or any other special diet (vegetarian diets are acceptable) in the month before the first study visit
  • Have had any abdominal surgery in the past (except removal of the appendix)
  • Have a known allergy to the antibiotics or antifungal medications used in this study, or to any of their ingredients
  • Have medical reasons that prevent them from receiving a medication called gentamicin (confirm with trial site)
  • Are currently taking part in any other interventional clinical trial
  • Are under legal protection orders (confirm with trial site)
  • Have abnormal blood test results at the screening visit, including problems with electrolytes, kidney markers, liver enzymes, thyroid hormone, or blood cell counts
  • Have had an infection requiring antibiotic treatment after the screening visit
  • Develop severe diarrhoea (seven or more extra stools per day above their normal level)

People with IBD may not be eligible if they:

  • Are pregnant or breastfeeding
  • Have donated blood in the three months before the study starts
  • Have taken antibiotic or antifungal medication by mouth in the three months before the first study visit
  • Have taken probiotic supplements in the month before the first study visit, or during the study
  • Have had more than 50 cm of the small intestine (ileum) surgically removed, or have had their colon removed
  • Have Crohn's disease that affects only the upper digestive tract (such as the oesophagus, stomach, or upper small intestine)
  • Have ulcerative colitis that affects only the rectum
  • Currently have a stoma (an opening in the abdomen to collect waste), have had one in the past six months, or have had any other abdominal surgery within the three months before joining
  • Are currently taking part in any other interventional clinical trial
  • Are under legal protection orders (confirm with trial site)
  • Have had an infection requiring antibiotic treatment after the screening visit
  • Experience a flare-up of their IBD during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Harry SOKOL, PU-PH, Assistance Publique - Hôpitaux de Paris

Phone: 00 33 1 49 28 31 62

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
2 January 2026
Est. completion
1 November 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Evaluate the impact of the gut microbiota, and of its alteration in inflammatory bowel disease, on peripheral immune cells energy metabolism

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov